Alkermes' New Drug Alixorexton Shows Promise in Narcolepsy Trial
Update: 2025-11-12
Description
Alkermes stock plummeted despite positive news on a new narcolepsy drug, alixorexton. The drug showed significant improvements in alertness and reduced daytime sleepiness in a study, with higher doses being statistically significant. Despite investor concerns, 95% of patients chose to continue with an extension study. Alixorexton is the first oral drug to show effectiveness in both narcolepsy types and was generally well-tolerated. Alkermes plans to share more results and start a global study in 2026.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
